drugset / Trial / NCT07131683

hUC-MSC-Exo Therapy for Autoimmune Encephalitis

NCT07131683

Phase 1/2 Not yet recruiting 38 enrolled Xuanwu Hospital, Beijing ECHO Biotech · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase I/IIa study to investigate the safety and preliminary efficacy of intranasal admnistration of human umbilical mesenchymal stem cell-derived exosome (hUC-MSC-Exo) for patients with autoimmune encephalitis.

Timeline

Start
2025-11-01
Primary completion
2027-06-30
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Other / unclassified 2.5e+10 unknown Intranasal
Subject Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Other / unclassified 5e+10 unknown Intranasal
Subject Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Other / unclassified 1e+11 unknown Intranasal